Birchview Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-59,365
| Closed | -$670K | – | 85 |
|
|
2025
Q4 | $670K | Buy |
+59,365
| New | +$670K | 0.39% | 49 |
|
|
2025
Q1 | – | Sell |
-7,365
| Closed | -$275K | – | 72 |
|
|
2024
Q4 | $275K | Hold |
7,365
| – | – | 0.22% | 51 |
|
|
2024
Q3 | $368K | Hold |
7,365
| – | – | 0.32% | 39 |
|
|
2024
Q2 | $256K | Hold |
7,365
| – | – | 0.24% | 46 |
|
|
2024
Q1 | $403K | Hold |
7,365
| – | – | 0.33% | 41 |
|
|
2023
Q4 | $315K | Buy |
+7,365
| New | +$315K | 0.25% | 42 |
|
|
2023
Q1 | – | Sell |
-7,365
| Closed | -$102K | – | 60 |
|
|
2022
Q4 | $102K | Sell |
7,365
-7,365
| -50% | -$1.12M | 0.07% | 53 |
|
|
2022
Q3 | $2.23M | Sell |
14,730
-270
| -2% | -$40K | 1.57% | 14 |
|
|
2022
Q2 | $2.19M | Buy |
15,000
+1,000
| +7% | +$128K | 1.59% | 14 |
|
|
2022
Q1 | $1.66M | Buy |
14,000
+2,000
| +17% | +$249K | 1.2% | 15 |
|
|
2021
Q4 | $1.65M | Buy |
12,000
+2,000
| +20% | +$254K | 1.07% | 17 |
|
|
2021
Q3 | $1.39M | Hold |
10,000
| – | – | 0.95% | 20 |
|
|
2021
Q2 | $971K | Hold |
10,000
| – | – | 0.58% | 31 |
|
|
2021
Q1 | $684K | Hold |
10,000
| – | – | 0.41% | 37 |
|
|
2020
Q4 | $857K | Hold |
10,000
| – | – | 0.49% | 31 |
|
|
2020
Q3 | $650K | Hold |
10,000
| – | – | 0.43% | 29 |
|
|
2020
Q2 | $731K | Hold |
10,000
| – | – | 0.44% | 31 |
|
|
2020
Q1 | $340K | Hold |
10,000
| – | – | 0.3% | 35 |
|
|
2019
Q4 | $544K | Buy |
+10,000
| New | +$495K | 0.4% | 33 |
|
Other funds holding BHVN
Birchview Capital's BHVN Position: Q1 2026 in Review
Birchview Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2026, closing a stake of 59,365 shares — an estimated $670K sold.
Birchview Capital first reported a position in BHVN in Q4 2019 and held it in 19 quarters. The position peaked at $2.23M in Q3 2022. 1 fund tracked by Wall St. Rank holds BHVN as of Q1 2026.
- Birchview Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2026 after selling out during the quarter.
- Birchview Capital sold 59,365 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2026, an estimated $670K.
- Birchview Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 19 quarters.
- Birchview Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.23M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2026.
Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.